Neurogene Inc. (NGNE) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.50
↑+78% vs avg
5yr avg: 1.40
30Y Low1.3·High76.4
ROE
↑
-31.4%
↓+91% vs avg
5yr avg: -364.7%
30Y Low-163%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NGNE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Neurogene Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $488M | $436M | $402M | $249M | $131M | $5.3B | $14.6B | $6.7B | $1.0B | $5.5B | $6.2B |
| Enterprise Value | $394M | $342M | $277M | $117M | $53M | $5.2B | $14.4B | $6.5B | $939M | $5.5B | $6.2B |
| P/E Ratio → | -7.37 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 434.14 | — | — | — | — | — | 40.64 | — | — |
| P/B Ratio | 2.50 | 1.65 | 1.29 | 1.34 | 1.32 | — | 76.43 | 47.01 | 13.98 | 55.78 | 43.13 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NGNE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 299.92 | — | — | — | — | — | 37.56 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NGNE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -31.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -251.0% | — | — | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | -8930.3% | — | — | — | — | — | -94.1% | — | — |
| Net Profit Margin | — | — | -8123.7% | — | — | — | — | — | -126.3% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.4% | -31.4% | -30.3% | -25.5% | -1634.7% | -101.7% | -20.0% | -64.8% | -36.8% | -41.2% | -29.2% |
| ROA | -28.9% | -28.9% | -26.9% | -21.9% | -52.4% | -32.4% | -18.6% | -61.8% | -33.6% | -37.9% | -27.6% |
| ROIC | -43.3% | -43.3% | -51.6% | -110.6% | — | — | -588.8% | — | -82.8% | -48.1% | -31.1% |
| ROCE | -34.8% | -34.8% | -31.8% | -36.8% | -58.5% | -34.5% | -24.1% | -22.7% | -27.3% | -41.9% | -29.7% |
NGNE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $104M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.09 | 0.05 | — | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.40 | -0.71 | -0.78 | — | -0.94 | -1.00 | -1.06 | -0.53 | -0.22 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -20641.60 | -20641.60 | -6261.00 | -4631.92 | -27593.50 | — | — | -69441.00 | -7895.25 | -12544.75 | -37001.00 |
Net cash position: cash ($104M) exceeds total debt ($10M)
NGNE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Neurogene Inc.'s current ratio of 16.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 8.72x to 16.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 16.56 | 16.56 | 20.84 | 8.72 | 12.74 | 6.81 | 24.66 | 30.28 | 16.68 | 9.93 | 10.87 |
| Quick Ratio | 16.56 | 16.56 | 20.84 | 8.72 | 12.74 | 6.64 | 24.66 | 30.28 | 16.68 | 9.93 | 10.87 |
| Cash Ratio | 16.39 | 16.39 | 20.61 | 8.58 | 12.33 | 6.50 | 24.41 | 30.17 | 16.63 | 9.87 | 10.83 |
| Asset Turnover | — | — | 0.00 | — | — | — | — | — | 0.32 | — | — |
| Inventory Turnover | — | — | — | — | — | 22.09 | — | — | — | — | — |
| Days Sales Outstanding | — | — | 255.70 | — | — | — | — | — | — | — | — |
NGNE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Neurogene Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $21M | $18M | $13M | $13M | $55M | $52M | $27M | $24M | $23M | $19M |
Peer Comparison
Compare NGNE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NGNEYou | $488M | -7.4 | — | — | — | — | -31.4% | -43.3% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 MNKD | $1B | 177.5 | 29.3 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See NGNE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NGNE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NGNE vs KRYS
Side-by-side business, growth, and profitability comparison vs Krystal Biotech, Inc..
Start ComparisonNGNE — Frequently Asked Questions
Quick answers to the most common questions about buying NGNE stock.
What is Neurogene Inc.'s P/E ratio?
Neurogene Inc.'s current P/E ratio is -7.4x. This places it at the 50th percentile of its historical range.
What is Neurogene Inc.'s ROE?
Neurogene Inc.'s return on equity (ROE) is -31.4%. The historical average is -56.0%.
Is NGNE stock overvalued?
Based on historical data, Neurogene Inc. is trading at a P/E of -7.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.